Sign In
Buy RVTY
$101.07
+0.680 (+0.677%)
At Close: Jun 03, 2026
Revvity cuts annual forecast on weak demand for diagnostics, contract research
08:11am, Monday, 30'th Oct 2023
Revvity Inc cut its full-year sales and revenue forecasts after missing Wall Street estimates for third-quarter results, hurt by weak demand for its supplies to life science researchers and diagnostic
Revvity's (RVTY) New Tie-Up to Boost NGS Research Workflow
12:47pm, Thursday, 19'th Oct 2023
Revvity's (RVTY) latest partnership is likely to address the workflow-related challenges faced by labs and democratize genomic sequencing.
Revvity (RVTY) Launches Three New Preclinical Research Systems
11:18am, Wednesday, 06'th Sep 2023
Revvity (RVTY) launches new preclinical imaging technologies for breakthrough discoveries. Learn how they can help advance research and boost Revvity's prospect.
Revvity, Inc. (RVTY) Q2 2023 Earnings Call Transcript
04:30am, Sunday, 06'th Aug 2023
Revvity, Inc. (NYSE:RVTY ) Q2 2023 Earnings Conference Call August 1, 2023 8:00 AM ET Company Participants Stephen Willoughby - Vice President of Investor Relations Prahlad Singh - President and Chief
Compared to Estimates, Revvity (RVTY) Q2 Earnings: A Look at Key Metrics
11:10am, Tuesday, 01'st Aug 2023
Although the revenue and EPS for Revvity (RVTY) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street e
Revvity (RVTY) Q2 Earnings and Revenues Top Estimates
08:55am, Tuesday, 01'st Aug 2023
Revvity (RVTY) came out with quarterly earnings of $1.21 per share, beating the Zacks Consensus Estimate of $1.18 per share. This compares to earnings of $2.32 per share a year ago.
Earnings Preview: Revvity (RVTY) Q2 Earnings Expected to Decline
11:38am, Tuesday, 25'th Jul 2023
Revvity (RVTY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Revvity: New Name - But New Investment Outlook? Reiterate Buy
04:00am, Tuesday, 18'th Jul 2023
Revvity, formerly PerkinElmer, has changed its name and made several updates to its investment outlook. It now has ~$2Bn to put to work following the sale of recent business units. I am still eyeing a
Revvity (RVTY) Launches Single Solution for Drug Development
01:18pm, Tuesday, 13'th Jun 2023
Revvity (RVTY) Signals Software suite integrates streamlining data, global monitoring and customizable workflows and covers the entire Make-Test-Decide lifecycle, which can be centrally managed.
Revvity (RVTY) Launches New System for Autoimmune Diagnostics
01:45pm, Tuesday, 06'th Jun 2023
Revvity's (RVTY) EUROIMMUN launches UNIQO 160, a new automated system for autoimmune disease diagnostics using indirect immunofluorescence test.
